Antibody Cocktail Therapy Given to First Covid-19 Patient in Ahmedabad

 



After the therapy was approved in India earlier this month, CIMS Hospital became the first private facility in Gujarat’s Ahmedabad to administer an antibody cocktail to a Covid-19 patient.


The monoclonal antibody cocktail treatment was launched in India just last week for treating mild Covid-19 patients. A 38-year-old diabetic male patient with Covid-19 symptoms were administered the antibody cocktail of Casirivimab and Imdevimab. CIMS is the first hospital in Ahmedabad to begin this treatment.


According to Doctors, the cocktail treatment is recommended only in the early stages of the Covid-19 infection and for high-risk patients. It is the same treatment that former US President Donald Trump received last year.


The patient we administered the combination medication today has diabetes and hence belongs to the high-risk group. The high mortality in young males during the second wave has been a grave concern for the medical fraternity. This medication is not recommended for Covid-19 patients who have moderate or severe disease with hypoxia.

According to the Covid Care Team of CIMS Hospital, the antibody cocktail therapy can be given to high-risk patients in the early stages of Covid-19 infection, displaying very mild or mild symptoms, and not having any oxygen requirement.

Comments

Popular posts from this blog

US-FDA has approved Eli Lilly and Company's new ultra rapid-acting insulin Lyumjev™ (Insulin lispro-aabc injection) for type 1 and type 2 diabetes.

CORONAVIRUS: AIIMS Study Claims Delta Variant Is Highly Infectious Even for Those Who Are Vaccinated.

Gas Leak at Maharashtra Chemical Factory, Residents Complain of Breathing Problems